Bold Business Releases Exclusive Interview with Christopher & Dana Reeve Foundation Covering Foundation’s Bold Next Steps to Cure Spinal Cord Paralysis

  NEW YORK, NY - 11/16/2017 (PRESS RELEASE JET)

After 25 years of research and over 139 million dollars donated towards the study of treating those living with spinal cord injuries, The Dana & Christopher Reeve Foundation have discovered a light at the end of the tunnel in a scientific breakthrough, the epidural stimulator and resulting steps to bring it to the over 5 million people with spinal cord injuries.

In an exclusive interview with The Christopher & Dana Reeve Foundation, Bold Business released a video and accompanying story featuring Reeve Foundation CEO, Peter Wilderotter and Vice Chairman, Henry Stifel.Wilderotter and Stifel provide new details on the Foundation’s work and progress towards its goal of “no more wheelchairs.”

Ed Kopko, CEO of Bold Business sat down with leaders of the Reeve Foundation to discuss the excitement behind The Reeve Foundation’s new era in scientific technology that is currently changing the lives of millions. Henry Stifel, Vice Chairman of the Board explained, “The Reeve Foundation funded research at many fine Universities over the years. The work done at Cal Tech, UCLA and University of Louisville led to the creation of tests and research on epidural stimulation.” The entire discussion with the key leaders and innovators has been published with the featured video on BoldBusiness.com.

The epidural stimulator, created with NeuroRecovery Technologies (NRT), treats those living with spinal cord injuries to aid in the movement of the affected areas. With this innovation, the future of those living with a spinal cord injury looks bright. NRT is known to work tirelessly to put scientific breakthroughs like these through the FDA approval process and get the products on the market. A partnership with NRT and Presidio Venture Partners creates a team striving to bring this unique scientific innovation to millions of patients. Jay Shepard, a Board member of both the NRT and The Reeve Foundation stated, “We are excited to see 2 very significant products in Neuromodulation being developed to help people with paralysis.”

The story also reveals, for the first time, details of the unique partnership and how the Reeve’s Foundation hopes to create Bold Societal Impact with the commercialization of epidural stimulators.

View the feature created by Bold Business, reporting on the breakthrough from The Reeve Foundation, NRT, and Presidio Venture Partners at BoldBusiness.com.

About the Reeve Foundation:

The Christopher & Dana Reeve Foundation is dedicated to curing spinal cord injury by funding innovative research and improving the quality of life for people living with paralysis through grants, information and advocacy. The Paralysis Resource Center (PRC) is the support side of the Reeve Foundation’s twin missions to provide “Today’s Care” and to strive for “Tomorrow’s Cure” and offers a free, comprehensive, national source of informational support for individuals living with paralysis and their caregivers. We meet all 20 of the Better Business Bureau’s standards for charity accountability and hold the BBB’s Charity Seal. For more information, please visit our website at www.ChristopherReeve.org or call 800-539-7309.

About Bold Business:

Bold Business is reports on business like no other business publication. It reports through the prism of how business positively impacts the world through the products and services they create. Bold reports on the exciting changes in the world that being implemented through 9 domains that affect people’s everyday lives, offering optimistic and insightful reporting. With countless stories already published on the domains of health, infrastructure, energy, and more, Bold’s focus is to report on brands that transform their ideas into bold actions that impact our society, such as the leading innovations made possible by the Christopher & Dana Reeve Foundation. The image and video accompanying this release may only be used within the context of this news release. Request permission from issuer for other u